Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. (Symbol: XERS) is a pioneering biopharmaceutical company committed to developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company's mission is to revolutionize patient care by creating ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices.
Xeris has successfully brought three groundbreaking products to market:
- Gvoke: A ready-to-use liquid glucagon designed to treat severe hypoglycemia, providing a critical solution for diabetic patients.
- Keveyis: The first FDA-approved therapy for primary periodic paralysis, offering relief for those suffering from this rare genetic disorder.
- Recorlev: Approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome, addressing a previously unmet need in this patient population.
In addition to these commercial successes, Xeris continues to innovate with a robust pipeline of development programs. Utilizing its proprietary formulation technologies, XeriSol and XeriJect, the company aims to bring new therapies to market that ease the administration and increase the efficacy of injectable treatments.
Financially, Xeris Biopharma Holdings has shown significant growth and resilience in a competitive market. Their strategic partnerships and collaborations further bolster their developmental and commercial capabilities, ensuring a steady pipeline of innovative products aimed at improving patient outcomes.
Recent achievements and ongoing projects underline Xeris' commitment to enhancing the quality of life for millions of patients globally. Keep up with the latest updates and news about Xeris Biopharma Holdings, Inc. to stay informed about their ongoing advancements and performance in the biopharmaceutical industry.
The American Diabetes Association (ADA) and Xeris Pharmaceuticals have announced a multi-year strategic partnership to promote awareness about glucagon prescriptions for diabetes patients. The collaboration focuses on emphasizing that all individuals with diabetes on blood glucose-lowering medications should have glucagon, preferably in ready-to-use form.
Key statistics highlight that up to 46% of type 1 diabetes patients and 21% of type 2 diabetes patients using insulin experience at least one severe hypoglycemia event annually. These events result in over 202,000 emergency department visits yearly, with 25% requiring hospitalization.
The partnership aims to develop educational materials and training resources for healthcare professionals and diabetes patients, alongside launching a national awareness campaign. The initiative aligns with ADA's updated Standards of Care in Diabetes—2025, addressing the critical need for proper glucagon prescription rates and emergency preparedness for those at risk of severe hypoglycemia.
Xeris Biopharma Holdings (XERS) has announced it expects to exceed its 2024 financial guidance with projected total revenue of $203 million, surpassing previous guidance of $198-$202 million. The company anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, achieving positive cash flow in Q4.
Q4 2024 highlights include $60 million in total revenue, representing 35% growth, with Recorlev® net revenue increasing approximately $5 million (28%) sequentially. Gvoke® achieved approximately 35% market share, while Keveyis® maintained stable patient numbers. The company received a $3 million milestone payment from Beta Bionics for developing a XeriSol® glucagon formulation. However, Amgen terminated its exclusive worldwide license agreement following a portfolio assessment.
Xeris Biopharma Holdings (XERS) has announced the granting of restricted stock units (RSUs) to 19 new employees as part of its Inducement Equity Plan. The Compensation Committee of Xeris' Board of Directors approved the grants on January 2, 2025, consisting of an aggregate of 181,500 shares of common stock.
The RSUs will vest over a three-year period in equal annual installments, contingent upon the employees' continued employment with Xeris or its subsidiaries. These equity awards were granted exclusively to new hires as an employment inducement under NASDAQ Listing Rule 5635(c)(4).
Xeris Biopharma Holdings (Nasdaq: XERS) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior management will engage in a fireside chat scheduled for December 3, 2024, at 8:00am Eastern Time. The event will be accessible through a live webcast on the 'Events & Presentations' section of Xeris' Investor Relations website, with a replay available for 30 days following the presentation.
Xeris Biopharma reported record Q3 2024 total revenue of $54.3M, with product revenue reaching $52.9M, marking a 27% increase year-over-year and 14% quarter-over-quarter growth. Gvoke revenue grew 29% to $22.9M, while Recorlev revenue surged 119% to $17.7M. However, Keveyis revenue declined 23% to $12.2M. The company raised its full-year revenue guidance to $198M-$202M and ended Q3 with $69.4M in cash. Net loss for Q3 was $15.7M or ($0.11) per share.
Xeris Biopharma Holdings (Nasdaq: XERS) has scheduled the release of its third quarter 2024 financial results before U.S. market opening on November 8, 2024. Management will host a conference call and webcast at 8:30 a.m. ET. The company, focused on developing innovative therapies, currently markets three products: Gvoke® for severe hypoglycemia, Keveyis® for primary periodic paralysis, and Recorlev® for endogenous Cushing's syndrome.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced the granting of restricted stock units (RSUs) to 42 new employees under its Inducement Equity Plan. The Compensation Committee of Xeris' Board of Directors approved the grant on October 1, 2024, for an aggregate of 364,000 shares of common stock.
These RSUs are designed as an inducement for new hires, in compliance with NASDAQ Listing Rule 5635(c)(4). The grants will vest over three years in equal annual installments, contingent on continued employment with Xeris or its subsidiaries. All awards are subject to the terms and conditions of Xeris' Inducement Equity Plan and relevant award agreements.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced its participation in three upcoming investor conferences in September 2024. The company will attend the 2024 Wells Fargo Healthcare Conference in Boston on September 4 for meetings only. At the H.C. Wainwright 26th Annual Global Investor Conference in New York on September 10, Xeris will participate in meetings and a fireside chat at 3:30pm ET. Lastly, the company will be present at the 2024 Cantor Global Healthcare Conference in New York on September 18 for meetings only.
Investors interested in 1x1 meetings should contact the conference sponsors directly. A webcast of the fireside chat will be available on Xeris' investor relations website. This participation in multiple conferences demonstrates Xeris' commitment to engaging with investors and showcasing its growth-oriented biopharmaceutical business.
Xeris Biopharma (Nasdaq: XERS) reported strong Q2 2024 financial results, with total revenue of $48.1M, including record product revenue of $46.5M. This represents an 18% increase over the prior quarter and a 26% increase year-over-year. The company tightened its full-year 2024 guidance, projecting total net revenue of $190M-$200M and a year-end cash balance of $60M-$75M.
Key highlights include:
- Gvoke revenue up 28% to $20.0M
- Recorlev revenue up 86% to $13.3M
- Keveyis revenue down 7% to $13.1M due to generic competition
- Cash position of $77.6M as of June 30, 2024
- Net loss of $15.0M for Q2 2024
The company also announced leadership changes, with John Shannon appointed as CEO and Kevin McCulloch promoted to President and COO.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced that it will release its second quarter 2023 financial results on Thursday, August 8, 2024, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss its financial and operational results.
Interested parties can pre-register for the call using the provided link. A replay of the conference call will be available until Thursday, August 22, 2024. The webcast can be accessed through the 'Events' section on the company's investor relations page or via the provided link.
FAQ
What is the current stock price of Xeris Biopharma Holdings (XERS)?
What is the market cap of Xeris Biopharma Holdings (XERS)?
What does Xeris Biopharma Holdings, Inc. specialize in?
What are the main products of Xeris Biopharma?
What is Gvoke used for?
What makes Xeris' therapies unique?
What proprietary technologies does Xeris use?
How many products has Xeris successfully commercialized?
What is Keveyis used for?
What is Recorlev approved to treat?
What are XeriSol and XeriJect?
Where can I find the latest news about Xeris Biopharma Holdings?
